WaveMan
WaveMan · Company
XNCR · Xencor Inc
> Search tickers & screens ⌘K
LIVE
← All companies

XNCR Xencor (XNCR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001326732
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
116
13F, latest reported quarter

What the filings say about XNCR

Insiders, 180 days
-$379.1K net sold
5 sellers · 0% of sales under a 10b5-1 plan

Xencor insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Xencor Inc insiders sold a net $379.1K of stock across 80 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Feigal Ellen
Director
SELL
2026-06-22 SECtraded 2026-06-18
6,843
$89.4K
+113.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2025.
  • The trade is 55.5% of the 12,340 shares held after it.
  • 4 other insiders sold within 30 days.
  • 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Feigal Ellen sold about $89.4K of XNCR on Jun 18, 2026; 4 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.
GORMAN KEVIN CHARLES
Director
SELL
2026-06-17 SECtraded 2026-06-15
7,527
$92.7K
+137.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jun 16, 2025.
  • The trade is 66.2% of the 11,378 shares held after it.
  • 4 other insiders sold within 30 days.
  • 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GORMAN KEVIN CHARLES sold about $92.7K of XNCR on Jun 15, 2026; 4 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.
GUSTAFSON KURT A
Director
SELL
2026-06-17 SECtraded 2026-06-15
5,474
$67.4K
+137.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 16, 2025.
  • The trade is 37.2% of the 14,709 shares held after it.
  • 4 other insiders sold within 30 days.
  • 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GUSTAFSON KURT A sold about $67.4K of XNCR on Jun 15, 2026; 4 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.
RANIERI RICHARD J
Director
SELL
2026-06-17 SECtraded 2026-06-15
5,474
$67.4K
+137.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2025.
  • The trade is 39.9% of the 13,709 shares held after it.
  • 4 other insiders sold within 30 days.
  • 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RANIERI RICHARD J sold about $67.4K of XNCR on Jun 15, 2026; 4 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.
Montgomery Alan Bruce
Director
SELL
2026-06-17 SECtraded 2026-06-15
5,064
$62.3K
+137.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 16, 2025.
  • The trade is 32.6% of the 15,547 shares held after it.
  • 4 other insiders sold within 30 days.
  • 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Montgomery Alan Bruce sold about $62.3K of XNCR on Jun 15, 2026; 4 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.
80 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 75 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$379.1K over 180 days
below 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
116 funds bought in last quarter
more than 74% of Pharma & Biotech
Revenue
+13.7% year over year
more than 63% of Pharma & Biotech
Margin
-73.2% net margin
below 54% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
30.2% of the float short (float per yahoo 2026-10-26) · 10.1 days to cover · settled 2026-09-30
more than 96% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch XNCR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+143.0%12M
-16%+37%+90%+143%2025-102025-122026-022026-042026-062026-082026-10 2025-12-19 · Dahiyat Bassil I sold $1.8M2025-12-19 · Desjarlais John R sold $1.2M2026-03-05 · Dahiyat Bassil I sold $167.3K2026-06-15 · GORMAN KEVIN CHARLES sold $92.7K2026-06-18 · Feigal Ellen sold $89.4K2026-03-03 · Dahiyat Bassil I sold $80.4K2026-03-06 · Dahiyat Bassil I sold $72.8K2026-06-15 · GUSTAFSON KURT A sold $67.4K2026-06-15 · RANIERI RICHARD J sold $67.4K2026-06-15 · Montgomery Alan Bruce sold $62.3K2026-03-05 · Desjarlais John R sold $46.3K2026-04-10 · Cornelissen Bart Jan sold $43.0K2026-03-05 · Eckert Celia sold $36.5K2026-03-03 · Desjarlais John R sold $31.7K2026-03-05 · Cornelissen Bart Jan sold $28.3K2026-03-06 · Desjarlais John R sold $27.6K2026-03-06 · Eckert Celia sold $19.5K2026-03-03 · Eckert Celia sold $17.8K2026-06-18 · Feigal Ellen filed to sell $89.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns XNCR: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
13,651,261 sh
$219.8M
PRIMECAP MANAGEMENT CO/CA/
10,181,322 sh
$163.9M
BVF INC/IL
7,133,720 sh
$114.9M
RTW INVESTMENTS, LP
6,777,461 sh
$109.1M
RA CAPITAL MANAGEMENT, L.P.
5,274,274 sh
$84.9M

Congress trades in XNCR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

XNCR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Feigal Ellen
Filed 2026-06-18
$89.4K

XNCR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
PRIMECAP Odyssey Aggressive Growth Fund
$128.0M position · as of 2026-07-31
1.7%
Virtus Biotech Clinical Trials Etf
$509.5K position · as of 2026-07-31
1.1%
PRIMECAP Odyssey Growth Fund
$62.6M position · as of 2026-07-31
1.0%
ALPS Medical Breakthroughs ETF
$898.1K position · as of 2026-05-31
0.6%
iShares Genomics Immunology and Healthcare ETF
$983.6K position · as of 2026-07-31
0.5%
Invesco S&P SmallCap Health Care ETF
$594.2K position · as of 2026-05-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
20 registered trials, 8 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
14
Phase 1
6 active
3
Phase 2
1 active
3
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Bassil Dahiyat
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.5M
$1.5M
$1.4M
-65%
+20%
2024
$6.8M
$2.6M
$3.1M
-47%
-9%
2023
$8.0M
$6.1M
$3.1M
-51%
-8%
2022
$7.7M
-$770.6K
$2.4M
-40%
-11%
2021
$5.4M
$317.3K
$2.1M
-8%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $379.1K sold by insiders over 180 days, 116 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

XNCR financials

Revenue growth
+13.7%
XBRL, annual
Net margin
-73.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$105.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-155.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$208.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.21x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-1.96x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-29.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-20.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-30.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.3B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-9.3%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$125.6M$110.5M$174.6M$164.6M
Operating income-$177.5M-$178.4M-$132.4M-$82.5M
Net income-$91.9M-$232.6M-$133.1M-$55.2M
EPS (diluted)-1.24-3.58-2.20-0.93
Operating cash flow-$135.1M-$202.2M-$77.9M$24.5M
Cash$54.1M$40.9M$53.8M$53.9M
Long-term debt$76.5M$115.2M$161.8M$0
SEC XBRL, fiscal years, as known on 2026-10-28

XNCR Stock Sonar score 6/7 axes

Find similar shapesCompare

XNCR ranks highest on institutional and government (74th percentile) and profitability (67th), and lowest on risk and compliance (8th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
67
Inputs
  • Return on equity-29.1% · 67 pct, sector of 545
  • Return on assets-20.4% · 66 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-30.3% · 67 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.21x · 45 pct, sector of 352
  • Cash flow to debt-1.96x · 45 pct, sector of 371
Growth
62
Inputs
  • Revenue growth, YoY+13.7% · 62 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
22
Inputs
  • Net Form 4 buying (codes P and S), 180d-$379K · 44 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
74
Inputs
  • Funds adding, latest quarter116 · 74 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
8
Inputs
  • Short interest, % of float+30.2% · 5 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+25.0% · 11 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

XNCR filings, in plain words

Are Xencor insiders buying or selling XNCR?

In the 180 days to 2026-10-28, Xencor insiders were net sellers, a net $379.1K across purchases and sales reported on Form 4, by 5 sellers.

Read the full summary

In the 180 days to 2026-10-28, Xencor insiders were net sellers of XNCR, a net $379.1K across purchases and sales reported on Form 4 by 5 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies